Merck & Co., Inc., disclosed in its August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30, 2011, that expert discovery in the NuvaRing litigation is expected to be completed by…
Merck & Co., Inc., is awaiting a court decision on its motion to dismiss a derivation action captioned Rose v. Hassan, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the…
Merck & Co., Inc., continues to defend lawsuits relating to average wholesale prices pending in various states, according to the Company’s August 8, 2011, Form 10-Q filing with the U.S. Securities and Exchange Commission for the quarter ended June 30,…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that the Texas Supreme Court has granted Merck s petition for review and scheduled oral argument for January 20,…
During the first nine months of 2009, Merck & Co. Inc. spent approximately US$190 million in the aggregate in legal defense costs worldwide, including US$65 million in the third quarter of 2009.
The legal expenses were related to (i) the Vioxx…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with U.S. Attorney s Office for the District of Massachusetts.
In March 2009, Merck received a…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that in the MDL proceeding of the Vioxx dispute, the trial of the Louisiana Attorney General case is scheduled…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it continues to respond to the subpoena sent by the State of California Attorney General in connection with…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that on September 8, 2009, plaintiff filed a second motion for rehearing en banc regarding the Texas state court…
Merck & Co. Inc. disclosed in its latest Quarterly Report on Form 10-Q filed with the U.S. Securities and Exchange Commission that it is cooperating with the U.S. Department of Justice regarding a probe centered on its Vioxx product activities.
The…